礼来宣布,将以现金高达24亿美元收购生物科技公司Orna Therapeutics。 Orna Therapeutics主要候选药物ORN-252旨在治疗B细胞驱动的自体免疫疾病,目前处于早期研发阶段。
礼来宣布,将以现金高达24亿美元收购生物科技公司Orna Therapeutics。 Orna Therapeutics主要候选药物ORN-252旨在治疗B细胞驱动的自体免疫疾病,目前处于早期研发阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.